NEW YORK, Nov. 12, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens today announced that Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer, will be presenting SIGA's progress in developing its lead drug candidate, ST-246, an antiviral for smallpox and other orthopoxviruses, to the World Health Organization (WHO) Advisory Committee on Variola Virus Research on November 19, 2008 in Geneva, Switzerland.
